S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

Asian stocks follow Wall St up as Powell says rates to rise

Tuesday, January 11, 2022 | Joe Mcdonald, AP Business Writer


People walk by an electronic stock board of a securities firm in Tokyo, Wednesday, Jan. 12, 2022. Asian stock markets followed Wall Street higher on Wednesday after Federal Reserve chairman Jerome Powell said monetary policy would return to normal and interest rates might be raised earlier than planned.(AP Photo/Koji Sasahara)

BEIJING (AP) — Asian stock markets followed Wall Street higher on Wednesday after Federal Reserve chairman Jerome Powell said monetary policy would return to normal and interest rates might be raised earlier than planned.

Shanghai, Tokyo, Hong Kong and Sydney advanced.

Wall Street's benchmark S&P 500 index rose 0.9% after Powell said policy “in all likelihood” will return to normal as bond purchases and other economic stimulus winds down. Speaking before the Senate Banking Committee, he said ultra-low rates might be raised earlier than planned if necessary to cool inflation that is at a four-decade high.

“Wall Street now has a better understanding on how the Fed will normalize policy,” Edward Moya of Oanda said in a report. “After Powell’s testimony, some investors feel they got the all-clear signal to buy the dip.”

The Shanghai Composite Index gained 0.3% to 3,579.74 and the Nikkei 225 in Tokyo rose 1.8% to 28,720.22. The Hang Seng in Hong Kong gained 2.2% to 24,256.72.

The Kospi in Seoul added 1.4% to 2,967.98 and Sydney's S&P-ASX 200 was 0.6% higher at 7,437.10.

India's Sensex opened up 0.8% at 61,084.46. New Zealand retreated while Southeast Asian markets gained.

Investors were rattled in mid-December when Fed officials said they would accelerate plans to wind down stimulus that is boosting stock prices. They have been trying to figure out how the world's biggest economy and financial markets will react.

On Tuesday, the S&P 500 broke a five-day series of declines and rose to 4,713.07. The Dow Jones Industrial Average gained 0.5% to 36,252.02. The Nasdaq composite advanced 1.4% to 15,153.45.

Apple rose 1.7% and chipmaker Nvidia rose 1.5%. Communication stocks and a mix of retailers and other companies that rely on direct consumer spending rose. Facebook parent Meta Platforms gained 1.9% and Gap rose 3%.

The World Bank cut its forecast for global economic growth this year to 4.1% from 4.3% due in part to supply chain disruptions that fueled inflation. The agency estimates the world economy grew by 5.5% in 2021.

On Wednesday, the U.S. government is due to report consumer inflation. That is followed Thursday by an index of wholesale prices.

In energy markets, benchmark U.S. crude rose 7 cents to $81.29 per barrel in electronic trading on the New York Mercantile Exchange. The contract rose $2.99 on Tuesday to $81.22. Brent crude, used as the price basis for international oils, lost 6 cents to $83.66 per barrel in London. It gained $2.85 the previous session to $83.72.

The dollar edged down to 115.34 yen from Tuesday's 115.37 yen. The euro rose to $1.1378 from $1.1366.


7 Great Biotech Stocks to Buy in Expectations of Better Days Ahead

The biotechnology (biotech) sector was one of the best performing sectors in 2020. Many companies saw their stock prices rise as the race was on for a Covid-19 vaccine.

However, many of these companies were pre-revenue companies. Or they were companies that only had one or two in-market products or therapies. And as the calendar turned to 2021, investors took notice. And what went up quickly went down. And in the case of the biotech sector, it came down hard.

One way to tell is to look at biotech ETFs. One of the most popular ETFs, the VanEck Vectors Biotech ETF (NYSEARCA:BBH) is down more than 15%. So you can imagine what it’s been like for many individual biotech stocks. If you’re a buy-and-hold investor, you’re licking some wounds right about now.

But investors who knew what companies to buy have done well. And many of those names will continue to lead the biotech sector in 2022. In this special presentation, we give investors seven biotech stocks that represent different aspects of this diverse sector. We’re confident there’s something for investors of all risk tolerances.

View the "7 Great Biotech Stocks to Buy in Expectations of Better Days Ahead".


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.